Look for Drugs and Conditions

Dextroamphetamine

Dextroamphetamine

Dextroamphetamine is a central nervous system stimulant medication. It belongs to the amphetamine class of drugs and works by increasing the levels of certain neurotransmitters in the brain, namely dopamine and norepinephrine. This action helps to improve focus, attention, and impulse control in individuals with attention deficit hyperactivity disorder (ADHD) and narcolepsy.

Indications

-Attention deficit hyperactivity disorder (ADHD) -Narcolepsy


Dosage

Dosage of dextroamphetamine should be individualized based on the patient's response and tolerance. The usual starting dose for ADHD in children is 5 mg once or twice daily, which can be gradually increased. For narcolepsy, the usual starting dose is 5 mg once or twice daily, with doses adjusted based on response.


Contra-Indications

-Hypersensitivity to dextroamphetamine or any component of the formulation -Advanced arteriosclerosis -Symptomatic cardiovascular disease -Severe hypertension -Hyperthyroidism -Glaucoma -Agitated states -History of drug abuse


Special Precautions

-Dextroamphetamine should be used with caution in patients with a history of substance abuse or addiction. -It should be used cautiously in patients with underlying cardiovascular conditions, including hypertension and structural heart abnormalities. -Regular monitoring of blood pressure, heart rate, and growth should be performed in pediatric patients receiving long-term treatment.


Side Effects

Common side effects of dextroamphetamine include: -Insomnia -Decreased appetite -Weight loss -Headache -Dry mouth -Nervousness -Irritability -Increased heart rate -Increased blood pressure -Dizziness -Blurred vision


Drug Interactions

Dextroamphetamine may interact with several medications, including: -Monoamine oxidase inhibitors (MAOIs) -Antidepressants -Antihypertensive agents -Antacids -Antipsychotics -Selective serotonin reuptake inhibitors (SSRIs) -Tricyclic antidepressants -Serotonin-norepinephrine reuptake inhibitors (SNRIs)


Ad 5